- Home
- TMP vs MYGN Comparison
TMP vs MYGN Comparison
Compare TMP & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMP
- MYGN
- Stock Information
- Founded
- TMP 1836
- MYGN 1991
- Country
- TMP United States
- MYGN United States
- Employees
- TMP N/A
- MYGN N/A
- Industry
- TMP Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TMP Finance
- MYGN Health Care
- Exchange
- TMP Nasdaq
- MYGN Nasdaq
- Market Cap
- TMP 878.2M
- MYGN 744.7M
- IPO Year
- TMP N/A
- MYGN 1995
- Fundamental
- Price
- TMP $65.26
- MYGN $4.51
- Analyst Decision
- TMP Buy
- MYGN Hold
- Analyst Count
- TMP 2
- MYGN 15
- Target Price
- TMP $69.00
- MYGN $15.14
- AVG Volume (30 Days)
- TMP 57.6K
- MYGN 1.3M
- Earning Date
- TMP 07-29-2025
- MYGN 08-05-2025
- Dividend Yield
- TMP 3.77%
- MYGN N/A
- EPS Growth
- TMP 980.13
- MYGN N/A
- EPS
- TMP 5.16
- MYGN N/A
- Revenue
- TMP $297,067,000.00
- MYGN $831,300,000.00
- Revenue This Year
- TMP $13.79
- MYGN N/A
- Revenue Next Year
- TMP $6.90
- MYGN $6.68
- P/E Ratio
- TMP $12.74
- MYGN N/A
- Revenue Growth
- TMP 40.19
- MYGN 7.38
- 52 Week Low
- TMP $53.41
- MYGN $3.81
- 52 Week High
- TMP $79.01
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- TMP 57.46
- MYGN 40.01
- Support Level
- TMP $63.65
- MYGN $4.97
- Resistance Level
- TMP $67.08
- MYGN $5.37
- Average True Range (ATR)
- TMP 1.54
- MYGN 0.28
- MACD
- TMP -0.06
- MYGN -0.07
- Stochastic Oscillator
- TMP 69.38
- MYGN 2.34
About TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.